Analystreport

Jounce Therapeutics, Inc. (NASDAQ: JNCE) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $20.00 price target on the stock.

Jounce Therapeutics, Inc.  (JNCE) 
Last jounce therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.jouncetx.com